Fatal Hemorrhage in a Patient with an Acquired Inhibitor of Human Thrombin

Albert R.la Spada, Bjã¸rn S. Skã¥lhegg, Ruth Henderson, Gottfried Schmer, Robert Pierce, Wayne Chandler

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Thrombin (factor IIa) is a serine protease that performs a number of functions in blood coagulation.1Among its most important actions is converting fibrinogen into fibrin monomers, which polymerize to form the fibrin clot. Thrombin participates in the activation of factors V, VIII, and XIII, as well as of platelets.2By binding to thrombomodulin on vascular endothelial cells, it forms a complex that activates protein C, thereby limiting the extent of an emerging clot.3Cleavage of thrombin's inactive zymogen precursor, prothrombin (factor II), is required to generate functionally active thrombin. Acquired inhibitors of certain coagulation factors are relatively common, but. . .

Original languageEnglish (US)
Pages (from-to)494-497
Number of pages4
JournalNew England Journal of Medicine
Issue number8
StatePublished - Aug 24 1995

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Fatal Hemorrhage in a Patient with an Acquired Inhibitor of Human Thrombin'. Together they form a unique fingerprint.

Cite this